<DOC>
	<DOCNO>NCT02473952</DOCNO>
	<brief_summary>The primary objective evaluate whether IGIV-C improve MG symptom compare placebo subject MG .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety IGIV-C Symptomatic Subjects With Generalized Myasthenia Gravis</brief_title>
	<detailed_description>The primary objective evaluate efficacy IGIV-C subject generalize myasthenia gravis ( MG ) standard care treatment study entry term improvement MG symptom measure mean change Quantitative Myasthenia Gravis ( QMG ) score Baseline ( Week 0 ) Week 24 compare placebo . The safety objective study evaluate safety tolerability IGIV-C loading dose 2 g/kg follow 7 maintenance dosage 1 g/kg every 3 week Week 21 subject MG .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Antiacetylcholine receptor ( AChR ) antibody positive Confirmed diagnosis generalize myasthenia gravis ( MG ) . Myasthenia Gravis Foundation America ( MGFA ) classification Class II , III , IVa inclusive Screening . QMG &gt; = 10 Screening . Note : Subjects history ocular MG may enroll . Receiving standard care MG treatment stable dose consist one follow time interval delineate ( time interval apply medication maintenance stable dose level ) : 1 . Cholinesterase inhibitor ( pyridostigmine equivalent ) least 2 week prior Screening immunosuppressant 2 . Cholinesterase inhibitor ( pyridostigmine equivalent ) least 2 week prior Screening AND/OR one following : 1 . Prednisone ( 60 mg/day equivalent ) least 2 month prior Screening , OR 2 . Azathioprine least 6 month prior Screening , OR 3 . Mycophenolate mofetil least 6 month prior Screening , OR 4 . Methotrexate least 6 month prior Screening , OR 5 . Cyclosporine tacrolimus least 3 month prior Screening 3 . Cholinesterase inhibitor ( pyridostigmine equivalent ) least 2 week prior Screening AND/OR prednisone ( 60 mg/day equivalent ) least one month prior Screening one following : 1 . Azathioprine least 6 month prior Screening , OR 2 . Mycophenolate mofetil least 6 month prior Screening , OR 3 . Methotrexate least 6 month prior Screening , OR 4 . Cyclosporine tacrolimus least 3 month prior Screening Have receive cyclophosphamide immunosuppressive agent apart one allow per inclusion criterion within past 6 month Any change MG treatment regimen Screening ( Week 3 , Visit 0 ) Baseline ( Week 0 , Visit 1 ) Greater two point change QMG score , increase decrease , Screening ( Week 3 , Visit 0 ) Baseline ( Week 0 , Visit 1 ) Any episode myasthenic crisis one month prior Screening Evidence malignancy within past 5 year ( nonmelanoma skin cancer , carcinoma situ cervix allow ) thymoma potentially require surgical intervention course trial ( intent perform thymectomy ) Thymectomy within precede 6 month Rituximab , belimumab , eculizumab monoclonal antibody use immunomodulation within past 12 month Have receive immune globulin ( Ig ) treatment give intravenous ( IV ) , subcutaneous , intramuscular route within last 3 month Current know hyperviscosity hypercoagulable state Currently receive anticoagulation therapy ( vitamin K antagonist , nonvitamin K antagonist oral anticoagulant [ e.g. , dabigatran etexilate , rivaroxaban , edoxaban , apixaban ] , parenteral anticoagulant [ e.g. , fondaparinux ] ) . Note oral antiplatelet agent allow ( e.g. , aspirin , clopidogrel , ticlodipine ) Documented diagnosis thrombotic complication polyclonal intravenous immunoglobulin ( IVIg ) therapy past History recent ( within last year ) myocardial infarction stroke Uncontrolled congestive heart failure ; embolism ; historically document ( within last year ) electrocardiogram ( ECG ) change indicative myocardial ischemia atrial fibrillation History chronic alcoholism illicit drug abuse ( addiction ) 12 month precede Screening/Week 3 ( Visit 0 ) Plasma exchange ( PLEX ) perform within last 2 month Renal impairment ( i.e. , serum creatinine exceed 1.5 time upper limit normal [ ULN ] expect normal range test laboratory ) . Hemoglobin level less 9 g per dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>